Plenty of MTX treatment following ivtreous injection of MTX in primaly intraoculat lymphoma
Phase 2
- Conditions
- Primaly intra ocular lymphoma
- Registration Number
- JPRN-jRCTs021180038
- Lead Sponsor
- itta Fumihiko
- Brief Summary
We prospectively evaluated the efficacy of combined therapy using intravitreal MTX and systemic high-dose MTX in 11 patients with confirmed diagnosis of PIOL. During treatment with intravitreal MTX injection, no patients experienced adverse event after the injection. The patient was recruited unsuccessfully, treatment was interrupted frequently, and the study was discontinued.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
Patient with intraouclatr lymphoma
Exclusion Criteria
Patient with poor general status
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method recurrence
- Secondary Outcome Measures
Name Time Method Evaluation of Vision and retina